Candid Summaries on CBD Studies

KEY TAKEAWAYS:

• During CBD treatment, dogs’ pain decreased with pain scores dropping from 21 to 14 (0-50 scale)
• Use of CBD oil result in a 12% increase in dogs’ activity 
• No side effects were reported by owners.  
• These clinic results suggest that the use of 2 mg/kg CBD twice a day can increase the comfort and activity of dogs suffering from osteoarthritis 

KEY TAKEAWAYS:

• 50 mg/day of CBD or 20 mg/day of liposomal CBD significantly reduced pain in dogs suffering from osteoarthritis
• Packaging CBD within a liposome (delivery method) forms liposomal CBD and improves CBD’s bioavailability and absorption 
• Movement indexes (standing, walking and running) were all improved after administration of both 50mg/day CBD and 20 mg/day liposomal CBD
• Dog’s quality of life increased after CBD treatment
• The study supports the safety and therapeutic potential of CBD for relieving arthritic pain and improving dog’s activity levels
• No detrimental impact of CBD administration was reported

KEY TAKEAWAYS:

• 43% of participants experienced a  ≥30% reduction in cancer-related pain intensity after cannabinoid treatment 
• 20% of cats and 25% of dogs will be diagnosed with cancer in their lifetime
• After 2 weeks of receiving CBD+THC in addition to all other treatments, there was a statistically significant reduction in pain severity when compared with placebo
• The addition of CBD resulted in a increase of 20% in the response rate 
• A greater proportion of patients in the cannabinoid treatment group reduced other pain medication doses whereas the highest proportion of increases in dose was in the placebo group
• Administration of THC+CBD was well tolerated and no safety concerns were identified 

KEY TAKEAWAYS:

• CBD reversed hyperalgesia after 7 days of oral treatment in 2 models of persistent pain in rats
• Repeated administration of CBD oil abolished/reduced the levels of molecules implicated in the pathogenesis of many inflammatory disorders and pain installation
• The study put into evidence the anti-hyperalgesic potency of CBD, while being a non-toxic and non-psychotropic agent 

KEY TAKEAWAYS:

• Topical CBD proved to be an effective symptomatic, anti-inflammatory and anti-hyperalgesic treatment in arthritis
• The subjects didn’t suffer any alteration in their activity levels or motor abilities.
• A dose of 6.2mg/day of CBD significantly reduced swelling and synovial thickness
• Transdermal CBD use improved pain, reducing the median score from 4 to 1.5 (0-5 scale)
• Only after 2 days of CBD treatment, there was a significant improvement of heat hypersensitivity, which persisted throughout the experiment
• Pro-inflammatory activity dropped as low as non-pathological levels after using CBD

KEY TAKEAWAYS:

• 95% of the dogs experienced decreased pain and improved mobility and quality of life after taking CBD oil
• Other pain-related medication already in use was eliminated in 43.5% of patients and reduced in 47.8% due to CBD contribution